We found that oncolytic VACV Pexa-vec (mJX-594) potently increased CD8+ T cells, including cancer antigen-specific CD8+ T cells, and decreased immunosuppressive cells in tumors irrespective of therapeutic efficacy (Figure 2). The gene discussed is CD8A; the disease is cancer.